Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2Other solid neoplasm 1Lymphoid 1

Conditions

Neoplasms 2

Interventions

pembrolizumab 18Nivolumab 18Gemcitabine 9Ipilimumab 8Cisplatin 8Carboplatin 8Capecitabine 8Paclitaxel 6Cetuximab 6atezolizumab 5Irinotecan 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5avelumab 4Trastuzumab 4Fluorouracil 4trametinib 3spartalizumab 3Specimen Handling 3Pemetrexed 3Leucovorin 3Everolimus 3Dexamethasone 3Biopsy 3urelumab 2toripalimab 2tislelizumab 2ribociclib 2repotrectinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × urelumab × Tumor-Agnostic × Clear all
NCT03792724 2019-01-03

INTRUST

Clinica Universidad de Navarra, Universidad de Navarra

Phase 1/2 Unknown
32 enrolled
Tumor-Agnostic

Neoplasms

NCT00309023 2015-10-12

Study of BMS-663513 in Patients With Advanced Cancer

Bristol-Myers Squibb

Phase 1/2 Terminated
115 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡